PressFebruary 29, 2024 Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
PressFebruary 29, 2024 Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
PressFebruary 29, 2024 atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
PressFebruary 27, 2024 Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
PressFebruary 27, 2024 Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds
PressFebruary 27, 2024 Red Light Holland to Export Its Largest Batch of Psilocybin to cGMP Lab in Canada, Under a 5th Health Canada Approved Psilocybin Import Permit to Partner CCrest Labs
PressFebruary 26, 2024 FSD Pharma Inc., Subsidiary Enter Agreement for Clinical Trial of Proprietary Blend Beverage
PressFebruary 23, 2024 Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
PressFebruary 21, 2024 Avesta Partners with Veterans Affairs (VA) to Offer Free Ketamine Therapy to Eligible Veterans
PressFebruary 20, 2024 Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
BlogFebruary 15, 2024 Robin Arnott & Sandeep Prakash are Building Meditative States Through Sound – Podcast Episode #46
PressFebruary 15, 2024 MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
Market ResearchFebruary 14, 2024 Unveiling the Mysteries of the Mind: A Landmark Event in New Orleans
